trending Market Intelligence /marketintelligence/en/news-insights/trending/tN42SsFNztMsQgEd3AiGZg2 content esgSubNav
In This List

European Commission extends market authorization of seizure drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


European Commission extends market authorization of seizure drug

The European Commission extended the marketed authorization of Zebinix to treat partial-onset seizures in children above the age of six.

The drug is already authorized for use in adults over the age of 18. It is marketed in Europe and Russia by Bial and by Bial's licensee, Eisai Europe Ltd.

Eisai Europe is an Eisai Co. Ltd. subsidiary.